Nexavar FDA Approval History
FDA Approved: Yes (First approved December 20, 2005)
Brand name: Nexavar
Generic name: sorafenib
Dosage form: Tablets
Company: Bayer HealthCare Pharmaceuticals Inc.
Treatment for: Renal Cell Carcinoma, Hepatocellular Carcinoma, Thyroid Cancer
Nexavar (sorafenib) is an oral multi-kinase inhibitor indicated for the treatment of hepatocellular carcinoma, renal cell carcinoma, and thyroid carcinoma.
Development timeline for Nexavar
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.